Outlook Therapeutics (NASDAQ: OTLK) stock was up by 34% since April 20. The main catalyst of the stock's rise during the period due to the company insiders repurchased the company's stock on April 20, that's a positive sign.

On the other hand, the company reported the positive results from its open-label safety study of ONS-5010 for the treatment of wet AMD and other retinal diseases at the end of March. The results demonstrated that ONS-5010 showed no unexpected safety trends and had a safety profile consistent with that of prior published data on the use of bevacizumab for ophthalmic conditions.

The results of this study are encouraging. If finally approved, ONS-5010 will be the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg to treat retinal diseases, and it will have 12 years of marketing exclusivity. The company said that the drug may become the first-line drug of choice in the United States for retinal indications.

The chronic eye disorder leaks fluid into the retina and causes blurred vision or blind spots, which can eventually lead to loss of sight. For the nearly 700,000 people who suffer from the disease in the US alone, and an estimated of $13.1 billion value from global anti-VEGF market.  

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.